Logiscreen

Neurocrine Biosciences Inc

$163.88
Market Cap 16.45B
ROE 21.6%
Gross Margin 98.3%
Debt/Equity 0.1
Current Ratio 2.9
Revenue QoQ 42.2%
EPS QoQ 23.6%
F-Score 5

About

Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.

Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Sector context

Healthcare

Fair Value

Trading at a discount to sector peers

P/E
25.12
vs median 31.50
P/B
4.93
vs median 2.17
ROE
0.22
vs median 0.09

Decent quality with acceptable fundamentals

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics